Stay up to date with notifications from The Independent

Notifications can be managed in browser preferences.

Roundup maker Monsanto defends weedkiller after being told to pay $289m to groundsman who blames it for his terminal cancer

Monsanto vice-president Scott Partridge said the company would appeal the verdict to 'vigorously defend' the weedkiller

Chiara Giordano
Saturday 11 August 2018 17:15 BST
Comments
Dewayne Johnson was diagnosed with non-Hodgkin's lymphoma in 2014
Dewayne Johnson was diagnosed with non-Hodgkin's lymphoma in 2014 (AP)

The maker of Roundup weedkiller has insisted it is safe despite being ordered to pay $289m to a school groundsman who claims it contributed to his terminal cancer.

In a landmark case, a jury in the US found that Monsanto's weedkiller, which contains the herbicide glyphosate, was a “substantial factor” in Dewayne Johnson’s illness and that the company failed to warn customers the product was dangerous.

Mr Johnson, 46, who was diagnosed with non-Hodgkin's lymphoma in 2014, was awarded the equivalent of £226m in damages on Friday having used Monsanto’s products Roundup and Ranger Pro in large quantities during the course of his work.

However Monsanto vice president Scott Partridge said the company would appeal the verdict to “vigorously defend this product”, claiming hundreds of studies showed the herbicide does not cause cancer.

“We all have sympathy for what Mr Johnson is going through; cancer is a terrible disease," Mr Partridge told BBC Radio 4’s Today programme on Saturday.

“I’ll tell you that this verdict doesn’t change the four plus decades of safe use and science behind the product.

“There have been over 800 medical scientific peer review published studies that have established there is no link whatsoever between glyphosate and adverse health effects, much less cancer."

Mr Johnson thanked jurors 'from the bottom of my heart', along with his lawyers and his family (AFP)

Roundup is one of the country's most popular weedkiller brands, while glyphosate herbicides are the most widely used herbicide in UK agriculture.

Environmentalists say the weedkiller is linked to cancer, although the claim is strongly denied by manufacturers and the EU has approved the chemical for use.

In 2016, a joint report by the World Health Organisation (WHO) and the UN said that, while there was “some evidence of a positive association between glyphosate exposure and risk of non-Hodgkin's lymphoma in some studies, the only large study of high quality found “no evidence of an association at any exposure level”.

It concluded that glyphosate “is unlikely to pose a carcinogenic risk to humans from exposure through the diet”.

It came after the France-based International Agency for Research on Cancer, which is part of the WHO, said in 2015 that glyphosate was a “probable human carcinogen”.

In September 2017, the European parliament banned Monsanto lobbyists from meeting MEPs and attending parliamentary inquiries after the chemical company refused to attend a hearing into allegations that it interfered with safety studies.

Academics and regulators were due to hear allegations that Monsanto exerted undue influence over studies about glyphosate, the key ingredient in its Roundup weedkiller.

However later that year the European Union extended the licence for use of glyphosate for five years.

The court heard Mr Johnson used the weedkiller in large amounts while working in the San Francisco Bay Area school district.

When using the product in windy conditions it would come into contact with his face, and on one occasion he was left soaked in the weedkiller when a hose broke.

Mr Johnson is said to have contacted Monsanto after developing a rash but was never warned it could cause cancer, according to lawyer Brent Wisner.

Johnson thanked jurors “from the bottom of my heart”, along with his lawyers and his family.

His was the first case filed by a cancer patient against the agribusiness giant to reach trial and his victory could set a precedent for many others.

Agencies contributed to this report

Join our commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in